Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

License Development and Commercialization Agreements (Details)

License Development and Commercialization Agreements (Details) - USD ($)
$ in Thousands
12 Months Ended
Sep. 14, 2020
Dec. 31, 2020
Dec. 31, 2019
License Development And Commercialization Agreements [Abstract]      
Upfront cash payment   $ 5,000  
Excercise option price amount $ 3,000 $ 89 $ 7
License agreement, description   In addition, the License Agreement provides for a one-time non-refundable option payments of $3,000 per Option Product ($9,000 in the aggregate), and up to $30,000 of milestone payments payable as follows: (i) $5,000 upon completion of the U.S. facility design, (ii) $5,000 upon completion of production of a specified amount of BioInk, and (iii) $5,000 for FDA marketing approval for each Covered Product (up to $20,000 in the aggregate).